AIDS Research and Treatment [41] M. L. Ntemgwa, T. D. Toni, B. G. Brenner, R. J. Camacho, and M. A. Wainberg, “Antiretroviral drug resistance in human immunodeﬁciency virus type 2,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 9, pp. 3611–3619, 2009. [42] L. Tong, S. Pav, C. Pargellis, F. Do, D. Lamarre, and P. C. Anderson, “Crystal structure of human immunodeﬁciency virus (HIV) type 2 protease in complex with a reduced amide inhibitor and comparison with HIV-1 protease structures,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 18, pp. 8387–8391, 1993. [43] F. Damond, F. Brun-Vezinet, S. Matheron et al., “Polymor- phism of the human immunodeﬁciency virus type 2 (HIV- 2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors,” Journal of Clinical Microbiology, vol. 43, no. 1, pp. 484–487, 2005. [44] M. Hightower and E. G. Kallas, “Diagnosis, antiretroviral therapy, and emergence of resistance to antiretroviral agents in HIV-2 infection: a review,” The Brazilian Journal of Infectious Diseases, vol. 7, no. 1, pp. 7–15, 2003. [45] P. Colson, M. Henry, C. Tourres et al., “Polymorphism and drug-selected mutations in the protease gene of human immunodeﬁciency virus type 2 from patients living in Southern France,” Journal of Clinical Microbiology, vol. 42, no. 2, pp. 570–577, 2004. [46] M. Ntemgwa, B. G. Brenner, M. Oliveira, D. Moisi, and M. A. Wainberg, “Natural polymorphisms in the human immunodeﬁciency virus type 2 protease can accelerate time to development of resistance to protease inhibitors,” Antimicrobial Agents and Chemotherapy, vol. 51, no. 2, pp. 604–610, 2007. [47] I. Pichova, J. Weber, J. Litera et al., “Peptide inhibitors of HIV-1 and HIV-2 proteases: a comparative study,” Leukemia, vol. 11, supplement 3, pp. 120–122, 1997. [48] B. Rode´s, C. Toro, J. A. Sheldon, V. Jime´nez, K. Mansinho, and V. Soriano, “High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART,” AIDS, vol. 20, no. 1, pp. 127–129, 2006. [49] J. A. Martin, M. A. Mobberley, S. Redshaw, A. Burke, A. S. Tyms, and T. A. Ryder, “The inhibitory activity of a peptide derivative against the growth of simian immunodeﬁciency virus in C8166 cells,” Biochemical and Biophysical Research Communications, vol. 176, no. 1, pp. 180–188, 1991. [50] A. K. Patick, H. Mo, M. Markowitz et al., “Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeﬁciency virus protease,” Antimicrobial Agents and Chemotherapy, vol. 40, no. 2, pp. 292–297, 1996. [51] J. P. Vacca, B. D. Dorsey, W. A. Schleif et al., “L-735,524: an orally bioavailable human immunodeﬁciency virus type 1 protease inhibitor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 9, pp. 4096–4100, 1994. [52] D. J. Kempf, K. C. Marsh, J. F. Denissen et al., “ABT-538 is a potent inhibitor of human immunodeﬁciency virus protease and has high oral bioavailability in humans,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 7, pp. 2484–2488, 1995. [53] B. Rode´s, J. Sheldon, C. Toro, V. Jime´nez, M. A. A´ lvarez, and V. Soriano, “Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy,” Journal of Antimicrobial Chemotherapy, vol. 57, no. 4, pp. 709–713, 2006. 9 [54] E. T. Brower, U. M. Bacha, Y. Kawasaki, and E. Freire, “Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use,” Chemical Biology and Drug Design, vol. 71, no. 4, pp. 298–305, 2008. [55] D. Desbois, B. Roquebert, G. Peytavin et al., “In vitro phenotypic susceptibility of human immunodeﬁciency virus type 2 clinical isolates to protease inhibitors,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 4, pp. 1545–1548, 2008. [56] R. A. Smith, S. E. Hawes, M. Toure et al., “Toward optimal antiretroviral therapy for HIV-2: can genotypic and phe- notypic drug resistance testing help guide therapy in HIV- 2?” in Proceedings of the 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif, USA, 2010, Abstract 597. [57] D. J. Kempf, J. D. Isaacson, M. S. King et al., “Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir ther- apy,” Antiviral Therapy, vol. 7, no. 3, pp. 165–174, 2002. [58] H. Mo, M. S. King, K. King, A. Molla, S. Brun, and D. J. Kempf, “Selection of resistance in protease inhibitor- experienced, human immunodeﬁciency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: muta- tion patterns and baseline correlates,” Journal of Virology, vol. 79, no. 6, pp. 3329–3338, 2005. [59] R. M. Kagan, M. D. Shenderovich, P. N. R. Heseltine, and K. Ramnarayan, “Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir,” Protein Science, vol. 14, no. 7, pp. 1870–1878, 2005. [60] J. Friend, N. Parkin, T. Liegler, J. N. Martin, and S. G. Deeks, “Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen,” AIDS, vol. 18, no. 14, pp. 1965–1966, 2004. [61] S. Masse, X. Lu, T. Dekhtyar et al., “In vitro selection and characterization of human immunodeﬁciency virus type 2 with decreased susceptibility to lopinavir,” Antimicrobial Agents and Chemotherapy, vol. 51, no. 9, pp. 3075–3080, 2007. [62] J. Ruelle, F. Roman, A. T. Vandenbroucke et al., “Transmit- ted drug resistance, selection of resistance mutations and moderate antiretroviral eﬃcacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database,” BMC Infectious Diseases, vol. 8, article no. 21, 2008. [63] F. S. Sarfo, D. F. Bibby, U. Schwab et al., “Inadvertent non-nucleoside reverse transcriptase inhibitor (NNRTI)- based antiretroviral therapy in dual HIV-1/2 and HIV-2 seropositive West Africans: a retrospective study,” Journal of Antimicrobial Chemotherapy, vol. 64, no. 3, pp. 667–669, 2009. [64] B. Rodes, C. Toro, R. Colombatti et al., “Selection of the K65R mutation in HIV-2 patients exposed to abacavir,” in Proceedings of the 15th Conference on Retrovirology and Opportunistic Infections, Boston, Mass, USA, 2008, Abstract 885. [65] A. Be´nard, F. Damond, P. Campa et al., “Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients,” AIDS, vol. 23, no. 9, pp. 1171–1173, 2009. [66] P. Barreiro and V. Soriano, “Suboptimal CD4 gains in HIV- infected patients receiving didanosine plus tenofovir,” Journal of Antimicrobial Chemotherapy, vol. 57, no. 5, pp. 806–809, 2006.